D
Donald M. Gleason
Researcher at Beth Israel Medical Center
Publications - 5
Citations - 3640
Donald M. Gleason is an academic researcher from Beth Israel Medical Center. The author has contributed to research in topics: Zoledronic acid & Placebo. The author has an hindex of 5, co-authored 5 publications receiving 3512 citations.
Papers
More filters
Journal ArticleDOI
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
Fred Saad,Donald M. Gleason,Robin Murray,Simon Tchekmedyian,Peter Venner,Louis Lacombe,Joseph L. Chin,Jeferson J. Vinholes,J. Allen Goas,Bee Chen +9 more
TL;DR: Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases and urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic Acid at either dose.
Journal ArticleDOI
Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer
Fred Saad,Donald M. Gleason,Robin Murray,Simon Tchekmedyian,Peter Venner,Louis Lacombe,Joseph L. Chin,Jeferson J. Vinholes,J. Allen Goas,Ming Zheng +9 more
TL;DR: Long-term treatment with 4 mg of zoledronic acid is safe and provides sustained clinical benefits for men with metastatic hormone-refractory metastatic prostate cancer.
Journal ArticleDOI
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Matthew R. Smith,James A. Eastham,Donald M. Gleason,Daniel Shasha,Simon Tchekmedyian,Norman Zinner +5 more
TL;DR: In this paper, a multicenter double-blind, randomized, placebo controlled clinical trial was performed to assess the effect of zoledronic acid, a potent new bisphosphonate, on bone mineral density during androgen deprivation therapy for nonmetastatic prostate cancer.
Journal ArticleDOI
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Allan Lipton,Eric J. Small,Fred Saad,Donald M. Gleason,David Gordon,Matthew R. Smith,Lee S. Rosen,M. Ortu Kowalski,Dirk J. Reitsma,John J. Seaman +9 more
TL;DR: Zoledonic acid is the first bisphosphonate to demonstrate efficacy in both lytic and blastic disease and was well tolerated with a safety profile similar to other IV bisph phosphonates.
Journal ArticleDOI
Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
TL;DR: It is suggested that long-term treatment with zoledronic acid provides continuing clinical benefit in patients with advanced prostate cancer, even after the occurrence of SREs.